Trial · NCT00045942
Adverse events4,914
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,914
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | PKC412 Core | 0 | 20 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Mutated PKC412 100 mg/Day (E1) | 3 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Mutated PKC412 200 mg/Day (E1) | 1 | 17 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 100 mg/Day (E1) | 7 | 33 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 200 mg/Day (E1) | 3 | 27 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Mutated PKC412 Dose Escalation (E2) | 3 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Mutated PKC+Itraconazole (E2) | 0 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 Dose Escalation (E2) | 4 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | FLT3 Wild Type PKC+Itraconazole (E2) | 4 | 6 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | PKC412 Core | 4 | 20 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Mutated PKC412 100 mg/Day (E1) | 0 | 18 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Mutated PKC412 200 mg/Day (E1) | 0 | 17 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 100 mg/Day (E1) | 0 | 33 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 200 mg/Day (E1) | 0 | 27 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Mutated PKC412 Dose Escalation (E2) | 0 | 9 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Mutated PKC+Itraconazole (E2) | 0 | 7 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Wild Type PKC412 Dose Escalation (E2) | 0 | 7 | |
| other | Anaemia NOS | Blood and lymphatic system disorders | FLT3 Wild Type PKC+Itraconazole (E2) | 0 | 6 | |
| other | Coagulopathy | Blood and lymphatic system disorders | PKC412 Core | 0 | 20 | |
| other | Coagulopathy | Blood and lymphatic system disorders | FLT3 Mutated PKC412 100 mg/Day (E1) | 0 | 18 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00045942/events